Pentwater Capital Management LP Verve Therapeutics, Inc. Put Options Transaction History
Pentwater Capital Management LP
- $15 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VERV
# of Institutions
195Shares Held
72.2MCall Options Held
452KPut Options Held
2.96M-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.19MShares$46.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4.1MShares$45.6 Million6.45% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.61MShares$40.2 Million0.18% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...